ExploRNA Therapeutics and Łukasiewicz - IChP Partner on GMP Manufacturing of mRNA Analogs
Biotechnology firm ExploRNA Therapeutics and research institute Łukasiewicz - IChP have entered a strategic partnership. The collaboration aims to advance Good Manufacturing Practice (GMP) for next-generation mRNA cap analogs.
ExploRNA Therapeutics, a biotechnology company focused on novel mRNA capping technologies, and the Łukasiewicz Research Network – Industrial Chemistry Institute (Łukasiewicz - IChP) have announced a strategic partnership. The collaboration will concentrate on advancing the Good Manufacturing Practice (GMP) production of next-generation mRNA cap analogs.
The partnership combines ExploRNA's expertise in mRNA capping with Łukasiewicz - IChP's capabilities in chemical process development and GMP manufacturing. This synergy is expected to facilitate the scaled-up production of essential mRNA components, crucial for the development and deployment of advanced mRNA-based therapeutics.
This initiative is designed to accelerate the supply chain for mRNA therapeutics, ensuring a reliable source of high-quality materials needed for clinical trials and potential commercialization. The goal is to support the growing demand for mRNA technology in various therapeutic applications.
By enhancing GMP manufacturing processes for these critical mRNA analogs, the partnership aims to contribute to the broader advancement of mRNA-based medicine, potentially enabling faster development of new treatments for a range of diseases.